Literature DB >> 33666735

Ferumoxytol-enhanced ultrashort TE MRA and quantitative morphometry of the human kidney vasculature.

Liam Timms1, Tianyi Zhou1, Yue Lyu1, Ju Qiao1, Vishala Mishra2, Rita Maria Lahoud2, Gayatri Veeramani Jayaraman3,4, Andrew S Allegretti3, David Drew5, Ravi T Seethamraju6, Mukesh Harisinghani2, Srinivas Sridhar7,8,9.   

Abstract

PURPOSE: To evaluate the feasibility of Quantitative Ultrashort-Time-to-Echo Contrast-Enhanced (QUTE-CE) MRA using ferumoxytol as a contrast agent for abdominal angiography in the kidney.
METHODS: Four subjects underwent ferumoxytol-enhanced MRA with the 3D UTE Spiral VIBE WIP sequence at 3 T. Image quality metrics were quantified, specifically the blood Signal-to-Noise Ratio (SNR), blood-tissue Contrast-to-Noise Ratio (CNR) and Intraluminal Signal Heterogeneity (ISH) from both the aorta and inferior vena cava (IVC). Morphometric analysis of the vessels was performed using manual approach and semi-automatic approach using Vascular Modeling ToolKit (VMTK). Image quality and branching order were compared between QUTE-CE MRA and the Gadolinium (Gd) CEMRA reference image.
RESULTS: QUTE-CE MRA provides a bright blood snapshot that delineates arteries and veins equally in the same scan. The maximum SNR and CNR values were 3,282 ± 1,218 and 1,295 ± 580, respectively - significantly higher than available literature values using other CEMRA techniques. QUTE-CE MRA had lower ISH and depicted higher vessel branching order (7th vs 3rd) within the kidney compared to a standard dynamic clinical Gd CEMRA scan. Morphometric analysis yielded quantitative results for the total kidney volume, total cyst volume and for diameters of the branching arterial network down to the 7th branch. Vessel curvature was significantly increased (p < 0.001) in the presence of a renal cyst compared to equivalent vessels in normal kidney regions.
CONCLUSION: QUTE-CE MRA is feasible for kidney angiography, providing greater detail of kidney vasculature, enabling quantitative morphometric analysis of the abdominal and intra-renal vessels and yielding metrics relevant to vascular diseases while using a contrast agent ferumoxytol that is safe for CKD patients.

Entities:  

Keywords:  Chronic kidney disease; Ferumoxytol; MRA; Ultrashort time-to-echo; Vascular

Mesh:

Substances:

Year:  2021        PMID: 33666735      PMCID: PMC8217117          DOI: 10.1007/s00261-021-02984-2

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  42 in total

1.  Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON).

Authors:  Matthias Stuber; Wesley D Gilson; Michael Schär; Dorota A Kedziorek; Lawrence V Hofmann; Saurabh Shah; Evert-Jan Vonken; Jeff W M Bulte; Dara L Kraitchman
Journal:  Magn Reson Med       Date:  2007-11       Impact factor: 4.668

Review 2.  Magnetic resonance angiography (MRA) in renally impaired patients: when and how.

Authors:  Georg Bongartz; Michael Mayr; Deniz Bilecen
Journal:  Eur J Radiol       Date:  2008-03-10       Impact factor: 3.528

Review 3.  Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.

Authors:  Nicola Schieda; Jason I Blaichman; Andreu F Costa; Rafael Glikstein; Casey Hurrell; Matthew James; Pejman Jabehdar Maralani; Wael Shabana; An Tang; Anne Tsampalieros; Christian van der Pol; Swapnil Hiremath
Journal:  Can Assoc Radiol J       Date:  2018-05       Impact factor: 2.248

4.  Appropriate Minimal Dose of Gadobutrol for 3D Time-Resolved MRA of the Supra-Aortic Arteries: Comparison with Conventional Single-Phase High-Resolution 3D Contrast-Enhanced MRA.

Authors:  S H Bak; H G Roh; W-J Moon; J W Choi; H S An
Journal:  AJNR Am J Neuroradiol       Date:  2017-05-04       Impact factor: 3.825

5.  Angiogenesis in autosomal-dominant polycystic kidney disease.

Authors:  E Bello-Reuss; K Holubec; S Rajaraman
Journal:  Kidney Int       Date:  2001-07       Impact factor: 10.612

6.  Biological Variability of Estimated GFR and Albuminuria in CKD.

Authors:  Sushrut S Waikar; Casey M Rebholz; Zihe Zheng; Shelley Hurwitz; Chi-Yuan Hsu; Harold I Feldman; Dawei Xie; Kathleen D Liu; Theodore E Mifflin; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Joseph V Bonventre; Lesley A Inker; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2018-07-18       Impact factor: 8.860

7.  Comparison of 0.5 M gadoterate and 1.0 M gadobutrol in peripheral MRA: a prospective, single-center, randomized, crossover, double-blind study.

Authors:  Stefan Haneder; Ulrike I Attenberger; Stefan O Schoenberg; Christian Loewe; Javier Arnaiz; Henrik J Michaely
Journal:  J Magn Reson Imaging       Date:  2012-07-30       Impact factor: 4.813

8.  3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium.

Authors:  Fabio S Raman; Marcelo S Nacif; George Cater; Neville Gai; Jacquin Jones; Debiao Li; Christopher T Sibley; Songtao Liu; David A Bluemke
Journal:  Int J Cardiovasc Imaging       Date:  2013-03-21       Impact factor: 2.357

9.  Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.

Authors:  Ashok Joseph Theruvath; Maryam Aghighi; Michael Iv; Hossein Nejadnik; Jonathan Lavezo; Laura Jean Pisani; Heike Elisabeth Daldrup-Link
Journal:  Nanotheranostics       Date:  2020-06-18

10.  Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.

Authors:  Nicholas M Selby; Peter J Blankestijn; Peter Boor; Christian Combe; Kai-Uwe Eckardt; Eli Eikefjord; Nuria Garcia-Fernandez; Xavier Golay; Isky Gordon; Nicolas Grenier; Paul D Hockings; Jens D Jensen; Jaap A Joles; Philip A Kalra; Bernhard K Krämer; Patrick B Mark; Iosif A Mendichovszky; Olivera Nikolic; Aghogho Odudu; Albert C M Ong; Alberto Ortiz; Menno Pruijm; Giuseppe Remuzzi; Jarle Rørvik; Sophie de Seigneux; Roslyn J Simms; Janka Slatinska; Paul Summers; Maarten W Taal; Harriet C Thoeny; Jean-Paul Vallée; Marcos Wolf; Anna Caroli; Steven Sourbron
Journal:  Nephrol Dial Transplant       Date:  2018-09-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.